Wäsch R - Search Results

1

Characterization of in vitro growth of multiple myeloma cells.

Zlei M, Egert S, Wider D, Ihorst G, Wäsch R, Engelhardt M. Zlei M, et al. Among authors: wasch r. Exp Hematol. 2007 Oct;35(10):1550-61. doi: 10.1016/j.exphem.2007.06.016. Exp Hematol. 2007. PMID: 17889722 Free article.

2

Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.

Wäsch R, Reisser S, Hahn J, Bertz H, Engelhardt M, Kunzmann R, Veelken H, Holler E, Finke J. Wäsch R, et al. Bone Marrow Transplant. 2000 Aug;26(3):243-50. doi: 10.1038/sj.bmt.1702512. Bone Marrow Transplant. 2000. PMID: 10967561 Clinical Trial.

3

Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation.

Engelhardt M, Bertz H, Wäsch R, Finke J. Engelhardt M, et al. Among authors: wasch r. Ann Hematol. 2001 Apr;80(4):201-8. doi: 10.1007/s002770100289. Ann Hematol. 2001. PMID: 11401085

4

Telomeres and telomerase in normal and leukemic hematopoietic cells.

Engelhardt M, Wäsch R, Guo Y. Engelhardt M, et al. Among authors: wasch r. Leuk Res. 2004 Oct;28(10):1001-4. doi: 10.1016/j.leukres.2004.01.015. Leuk Res. 2004. PMID: 15289009

5

Telomere length and hTERT expression in patients with acute myeloid leukemia correlate with karyotypic instability.

Engelhardt M, Wäsch R. Engelhardt M, et al. Among authors: wasch r. Haematologica. 2005 Mar;90(3):289B. Haematologica. 2005. PMID: 15749652 No abstract available.

6

Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient.

Engelhardt M, Müller AM, Maier W, Wäsch R. Engelhardt M, et al. Among authors: wasch r. Leukemia. 2005 May;19(5):869-70. doi: 10.1038/sj.leu.2403723. Leukemia. 2005. PMID: 15772697 No abstract available.

7

Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation.

Zeiser R, Spyridonidis A, Wäsch R, Ihorst G, Grüllich C, Bertz H, Finke J. Zeiser R, et al. Among authors: wasch r. Leukemia. 2005 May;19(5):814-21. doi: 10.1038/sj.leu.2403719. Leukemia. 2005. PMID: 15772700

8

Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.

Spyridonidis A, Küttler T, Wäsch R, Samek E, Waterhouse M, Behringer D, Bertz H, Finke J. Spyridonidis A, et al. Among authors: wasch r. Stem Cells Dev. 2005 Apr;14(2):213-22. doi: 10.1089/scd.2005.14.213. Stem Cells Dev. 2005. PMID: 15910248

9

State of the art therapy in multiple myeloma and future perspectives.

Denz U, Haas PS, Wäsch R, Einsele H, Engelhardt M. Denz U, et al. Among authors: wasch r. Eur J Cancer. 2006 Jul;42(11):1591-600. doi: 10.1016/j.ejca.2005.11.040. Epub 2006 Jul 3. Eur J Cancer. 2006. PMID: 16815703 Review.

10

[Origin and role of aneuploidy in cancer].

Schnerch D, Hasskarl J, Engelhardt M, Wäsch R. Schnerch D, et al. Among authors: wasch r. Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1747-53. doi: 10.1055/s-2006-947828. Dtsch Med Wochenschr. 2006. PMID: 16868879 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

201 results

Search Page

Filters